FAS and neoplasm: Using PPC1 prostate cancer cells, we determined that stimulation with low dose anti-Fas antibody CH11 (3 ng/ml) did not result in cytotoxicity, while stimulation with high dose anti-Fas antibody (25 ng/ml) killed these tumor cells.